BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25379850)

  • 1. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.
    Koen Talsma A; Shapiro J; Looman CW; van Hagen P; Steyerberg EW; van der Gaast A; van Berge Henegouwen MI; Wijnhoven BP; van Lanschot JJ; ; Hulshof MC; van Laarhoven HW; Nieuwenhuijzen GA; Hospers GA; Bonenkamp JJ; Cuesta MA; Blaisse RJ; Busch OR; ten Kate FJ; Creemers GJ; Punt CJ; Plukker JT; Verheul HM; van Dekken H; van der Sangen MJ; Rozema T; Biermann K; Beukema JC; Piet AH; van Rij CM; Reinders JG; Tilanus HW
    Ann Surg; 2014 Nov; 260(5):786-92; discussion 792-3. PubMed ID: 25379850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
    Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy.
    Noordman BJ; van Klaveren D; van Berge Henegouwen MI; Wijnhoven BPL; Gisbertz SS; Lagarde SM; van der Gaast A; Hulshof MCCM; Biermann K; Steyerberg EW; van Lanschot JJB;
    Ann Surg; 2018 May; 267(5):892-897. PubMed ID: 28350565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial.
    Robb WB; Dahan L; Mornex F; Maillard E; Thomas PA; Meunier B; Boige V; Pezet D; Le Brun-Ly V; Bosset JF; Mabrut JY; Triboulet JP; Bedenne L; Seitz JF; Mariette C;
    Ann Surg; 2015 May; 261(5):902-8. PubMed ID: 25361220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Impact of Total Resected Lymph Nodes in Esophageal Cancer Patients With and Without Neoadjuvant Chemoradiation.
    Ho HJ; Chen HS; Hung WH; Hsu PK; Wu SC; Chen HC; Wang BY
    Ann Surg Oncol; 2018 Dec; 25(13):3820-3832. PubMed ID: 30284131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.
    Phillips AW; Lagarde SM; Navidi M; Disep B; Griffin SM
    Ann Surg; 2017 Apr; 265(4):750-756. PubMed ID: 27467444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
    Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
    Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
    Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
    Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy.
    Miyata H; Yamasaki M; Makino T; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    J Surg Oncol; 2015 Jul; 112(1):60-5. PubMed ID: 26179950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa.
    Shapiro J; ten Kate FJ; van Hagen P; Biermann K; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2013 Nov; 258(5):678-88; discussion 688-9. PubMed ID: 24096766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
    Klevebro F; Johnsen G; Johnson E; Viste A; Myrnäs T; Szabo E; Jacobsen AB; Friesland S; Tsai JA; Persson S; Lindblad M; Lundell L; Nilsson M
    Eur J Surg Oncol; 2015 Jul; 41(7):920-6. PubMed ID: 25908010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
    Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Extracapsular Lymph Node Involvement After Neoadjuvant Chemoradiation Therapy Followed by Surgery in Carcinoma of the Esophagus: A Multicenter Study.
    Depypere LP; Moons J; Mariette C; D'Journo XB; Thomas PA; Hölscher AH; Bollschweiler E; van Berge-Henegouwen MI; Van Lanschot JJB; Lerut TEMR; Nafteux PR
    Ann Surg; 2018 Dec; 268(6):1000-1007. PubMed ID: 28742714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent.
    Mariette C; Piessen G; Briez N; Triboulet JP
    Ann Surg; 2008 Feb; 247(2):365-71. PubMed ID: 18216546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy.
    Giugliano DN; Berger AC; Pucci MJ; Rosato EL; Evans NR; Meidl H; Lamb C; Levine D; Palazzo F
    J Gastrointest Surg; 2017 Sep; 21(9):1377-1384. PubMed ID: 28664255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of the Location of Lymph Node Metastases in Patients With Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction.
    Anderegg MC; Lagarde SM; Jagadesham VP; Gisbertz SS; Immanuel A; Meijer SL; Hulshof MC; Bergman JJ; van Laarhoven HW; Griffin SM; van Berge Henegouwen MI
    Ann Surg; 2016 Nov; 264(5):847-853. PubMed ID: 27429034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.